# A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct06878625/  
OnCo record `nct06878625` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.

## Summary

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT06878625 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 138 participants, started 2024-12-06 and due to reach its primary completion in 2027-06-30. Interventions recorded: Sacituzumab Govitecan combined with Toripalimab; Sacituzumab govitecan combined with anti-angiogenesis. Conditions listed: Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically confirmed triple-negative invasive breast cancer, defined as immunohistochemical detection of ER \< 10%, PR \< 10%, HER2 0-1+ or HER2 2+ with negative FISH or CISH results, in accordance with the 2018 ASCO-CAP HER2-negative identification guidelines". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06878625
- Phase: 2
- Setting: A Multicenter, Prospective, Cohort Study Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT06878625: https://clinicaltrials.gov/study/NCT06878625

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06878625.json